NASDAQ:SAVA

Cassava Sciences - SAVA Stock Forecast, Price & News

$23.71

-2.00 (-7.78%)

(As of 03/22/2023 03:52 PM ET)

Add

Compare

Today's Range: $23.58
▼
$25.73
50-Day Range: $24.70
▼
$36.44
52-Week Range: $13.84
▼
$51.59

Volume: 1.46 million shs
Average Volume: 1.33 million shs
Market Capitalization: $989.89 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $54.33

Institutional Ownership

Cassava Sciences MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 129.3% Upside
$54.33 Price Target
Short Interest: Bearish
28.69% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.82
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Acquiring Shares
$302,193 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.76) to ($3.31) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

616th out of 983 stocks

Pharmaceutical Preparations Industry

295th out of 478 stocks

3.0

Analyst's Opinion

Consensus Rating
Cassava Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $54.33, Cassava Sciences has a forecasted upside of 129.3% from its current price of $23.70.
Amount of Analyst Coverage
Cassava Sciences has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
28.69% of the float of Cassava Sciences has been sold short.
Short Interest Ratio / Days to Cover
Cassava Sciences has a short interest ratio ("days to cover") of 7.9.
Change versus previous month
Short interest in Cassava Sciences has recently increased by 3.87%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Cassava Sciences does not currently pay a dividend.
Dividend Growth
Cassava Sciences does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Cassava Sciences has received a 74.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for Alzheimer" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Cassava Sciences is -0.82.

2.2

News and Social Media Coverage

News Sentiment
Cassava Sciences has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Cassava Sciences this week, compared to 3 articles on an average week.
Search Interest
Only 46 people have searched for SAVA on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.
MarketBeat Follows
Only 15 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -59% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cassava Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $302,193.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
10.10% of the stock of Cassava Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 25.51% of the stock of Cassava Sciences is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Cassava Sciences are expected to decrease in the coming year, from ($0.76) to ($3.31) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cassava Sciences is -12.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cassava Sciences is -12.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cassava Sciences has a P/B Ratio of 4.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cassava Sciences (NASDAQ:SAVA) Stock

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Receive SAVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.

SAVA Stock News Headlines

March 17, 2023 | finance.yahoo.com

3 Short-Squeeze Stocks to Keep on Your Radar

March 12, 2023 | seekingalpha.com

A Comparison Between Cassava Sciences' Simufilam, Aricept, Anavex's Blarcamesine, And Panax Ginseng For The Treatment Of Alzheimer's Disease

March 22, 2023 | Weiss Ratings (Ad)

Fed's Shocking New Plan to Control Your Money

The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 

March 9, 2023 | msn.com

This Insider Just Spiked Investors’ Interest in Cassava (NASDAQ:SAVA) Stock

March 8, 2023 | msn.com

Cassava Sciences up 9% on director's ~$2.3M share purchases

March 8, 2023 | benzinga.com

Cassava Sciences shares are trading higher following the purchase of 88,841 shares by a company director.

March 8, 2023 | markets.businessinsider.com

Why Cassava Sciences Stock Is Surging After Hours

March 6, 2023 | finance.yahoo.com

The three-year returns have been massive for Cassava Sciences (NASDAQ:SAVA) shareholders despite underlying losses increasing

March 22, 2023 | Weiss Ratings (Ad)

Fed's Shocking New Plan to Control Your Money

March 5, 2023 | seekingalpha.com

Cassava Sciences: Open Label Study Data Unconvincing But Indicative Of Good Things

March 3, 2023 | finance.yahoo.com

Q4 2022 Lexicon Pharmaceuticals Inc Earnings Call

February 28, 2023 | finanznachrichten.de

Cassava Sciences, Inc.: Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates

February 28, 2023 | finance.yahoo.com

Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates

February 8, 2023 | msn.com

Cassava Sciences plans to complete enrollment for phase simufilam studies by year end

February 8, 2023 | finance.yahoo.com

Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease

February 1, 2023 | finance.yahoo.com

3 Big Reasons to Sell Cassava Sciences Stock Right Now

January 31, 2023 | benzinga.com

If You Invested $100 In This Stock 5 Years Ago, You Would Have $400 Today

January 30, 2023 | seekingalpha.com

Cassava Sciences And Alzheimer's Disease: Unravelling The Data

January 27, 2023 | seekingalpha.com

Cassava Sciences' Data Once Again Misunderstood

January 26, 2023 | seekingalpha.com

Cassava Sciences: Data For Mild Alzheimer's Disease Patients Provides Good Risk/Reward Profile

January 24, 2023 | msn.com

Tesla, Amazon, Microsoft, Cassava Sciences, Intuitive Surgical: Why These 5 Stocks Are Drawing Investors' Attention Today

January 24, 2023 | investorplace.com

Why Is Cassava Sciences (SAVA) Stock Down 20% Today?

January 24, 2023 | msn.com

Cassava Sciences Shares Fall As Alzheimer's Candidate Worsens Patients With Moderate Disease

January 24, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Cassava Sciences (SAVA)

January 24, 2023 | msn.com

Cassava Sciences falls 17% after reporting mid-stage data for Alzheimer’s candidate

January 24, 2023 | finance.yahoo.com

Cassava Plummets As 'Highly Desirable' Alzheimer's Results Don't Cut It With Investors

January 24, 2023 | finance.yahoo.com

Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive SAVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.

SAVA Company Calendar

Last Earnings: 11/10/2021
Today: 3/22/2023
Next Earnings (Estimated): 5/04/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SAVA
CUSIP: N/A
CIK: 1069530
Web: www.cassavasciences.com
Phone: (512) 501-2444
Fax: 512-501-0414
Employees: 24
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $54.33
High Stock Price Forecast: $124.00
Low Stock Price Forecast: $11.00
Forecasted Upside/Downside: +111.3%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.90)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-76,250,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -34.59%
Return on Assets: -33.38%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 29.91
Quick Ratio: 29.91

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.68 per share
Price / Book: 4.53

Miscellaneous

Outstanding Shares: 41,750,000
Free Float: 37,532,000
Market Cap: $1.07 billion
Optionable: Not Optionable
Beta: -0.10

Key Executives

Remi Barbier
Chairman, President & Chief Executive Officer

Eric J. Schoen
Chief Financial Officer

James W. Kupiec
Chief Medical Officer

Michael Zamloot
Senior Vice President-Technical Operations

George B. Thornton
Senior Vice President-Technology

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SAVA Stock - Frequently Asked Questions

Should I buy or sell Cassava Sciences stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SAVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAVA, but not buy additional shares or sell existing shares.
View SAVA analyst ratings or view top-rated stocks.
What is Cassava Sciences' stock price forecast for 2023?: 3 analysts have issued 12-month price objectives for Cassava Sciences' shares. Their SAVA share price forecasts range from $11.00 to $124.00. On average, they predict the company's share price to reach $54.33 in the next twelve months. This suggests a possible upside of 112.2% from the stock's current price.
View analysts price targets for SAVA or view top-rated stocks among Wall Street analysts.
How have SAVA shares performed in 2023?: Cassava Sciences' stock was trading at $29.54 at the beginning of 2023. Since then, SAVA stock has decreased by 13.3% and is now trading at $25.60.
View the best growth stocks for 2023 here.
When is Cassava Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our SAVA earnings forecast.
How were Cassava Sciences' earnings last quarter?: Cassava Sciences, Inc. (NASDAQ:SAVA) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.09.
What ETFs hold Cassava Sciences' stock?: ETFs with the largest weight of Cassava Sciences (NASDAQ:SAVA) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Invesco Dynamic Biotechnology & Genome ETF (PBE), iShares Neuroscience and Healthcare ETF (IBRN), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco DWA Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and iShares U.S. Pharmaceuticals ETF (IHE).

When did Cassava Sciences' stock split?: Cassava Sciences shares reverse split before market open on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.
What other stocks do shareholders of Cassava Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA).
What is Cassava Sciences' stock symbol?: Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA."
Who are Cassava Sciences' major shareholders?: Cassava Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Jefferies Financial Group Inc. (0.00%), Geode Capital Management LLC (1.77%), Susquehanna International Group LLP (0.00%), Group One Trading L.P. (0.00%), Norges Bank (0.82%) and Charles Schwab Investment Management Inc. (0.70%). Insiders that own company stock include Eric Schoen, James William Kupiec, Remi Barbier, Richard Barry and Sanford Robertson.
View institutional ownership trends.
How do I buy shares of Cassava Sciences?: Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Cassava Sciences' stock price today?: One share of SAVA stock can currently be purchased for approximately $25.60.
How much money does Cassava Sciences make?: Cassava Sciences (NASDAQ:SAVA) has a market capitalization of $1.07 billion. The company earns $-76,250,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis.
How can I contact Cassava Sciences?: Cassava Sciences' mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The official website for the company is www.cassavasciences.com. The company can be reached via phone at (512) 501-2444, via email at ir@paintrials.com, or via fax at 512-501-0414.

This page (NASDAQ:SAVA) was last updated on 3/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cassava Sciences - SAVA Stock Forecast, Price & News

Cassava Sciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Cassava Sciences (NASDAQ:SAVA) Stock

SAVA Stock News Headlines

SAVA Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

SAVA Stock - Frequently Asked Questions

Overall MarketRank^™